Steven Myers - Caladrius Biosciences Independent Director
CLBSDelisted Stock | USD 0.43 0.39 895.37% |
Director
Mr. Steven S. Myers is an Independent Director of the Company. Steven S. Myers joined the Board in November 2006. He currently serves as Interim Chairman, Lead Independent Director and Chairperson of the Governance Nominating Committee. He also serves on the Audit and Compensation Committees. He graduated from Stanford University with a B.S. in Mathematics. He is a fourtime serial entrepreneur, an Ernst Young Entrepreneur of the Year for Software and Information Services, and a recipient of the California Governors Special Recognition Award. Mr. Myers is a director of several other companies. He has conducted business in a dozen countries in Europe and Asia. His private equity investment company, Dolphin Capital Holdings, Inc. invests in companies with innovative business strategies. Portfolio investments include regenerative medicine, biotechnology, medical devices, applied materials development, alternative energy, distressed debt, and for income real estate. An Administration policy advisor on Cyber Security, he served in 2012 on the Department of Homeland Security Task Force on Cyber Security Resources and briefed thenDHS Secretary Napolitano on the Task Force recommendations. He was recently appointed to a third term on the U.S. State Department Advisory Committee on International Economic Policy, which advises the Secretary of State on foreign policy issues. At the Pacific Council on International Policy he serves on the Board of Directors and is Chairman of their National Security Member Committee. Mr. Myers founded SMA, an Aerospace Defense Industry management consulting firm that over 25 years grew to approximately 100 million in annual revenue and over 800 employees spearheading industrychanging innovations in competing for and managing U.S. Government contracts. During his tenure the company managed more than 360 billion in major program competitions since 2006.
Age | 70 |
Tenure | 18 years |
Phone | 908 842-0100 |
Web | www.caladrius.com |
Caladrius Biosciences Management Efficiency
The company has return on total asset (ROA) of (16.73) % which means that it has lost $16.73 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (23.84) %, meaning that it generated substantial loss on money invested by shareholders. Caladrius Biosciences' management efficiency ratios could be used to measure how well Caladrius Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 626 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Caladrius Biosciences has a current ratio of 31.73, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Caladrius Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Caladrius Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Caladrius Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Caladrius to invest in growth at high rates of return. When we think about Caladrius Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Bobby OBrien | Valhi Inc | 58 | |
Annie Goodwin | Glacier Bancorp | 62 | |
David Rawlinson | Discover Financial Services | 44 | |
Humberto Alfonso | Eastman Chemical | 63 | |
Michael Connors | Eastman Chemical | 62 | |
George Sutton | Glacier Bancorp | 72 | |
Jeffrey Aronin | Discover Financial Services | 53 | |
Dallas Herron | Glacier Bancorp | 73 | |
Thomas Barry | Valhi Inc | 76 | |
John Murdoch | Glacier Bancorp | 75 | |
Jennifer Wong | Discover Financial Services | 46 | |
Norman Edelcup | Valhi Inc | 78 | |
Vanessa Sutherland | Eastman Chemical | 48 | |
Kim Mink | Eastman Chemical | 61 | |
Mark Semmens | Glacier Bancorp | 57 | |
John Owen | Discover Financial Services | 63 | |
Lewis Kling | Eastman Chemical | 73 | |
Mary Tidlund | Valhi Inc | 63 | |
James Brien | Eastman Chemical | 62 | |
Candace Duncan | Discover Financial Services | 67 | |
David Raisbeck | Eastman Chemical | 71 |
Management Performance
Return On Equity | -23.84 | |||
Return On Asset | -16.73 |
Caladrius Biosciences Leadership Team
Elected by the shareholders, the Caladrius Biosciences' board of directors comprises two types of representatives: Caladrius Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Caladrius. The board's role is to monitor Caladrius Biosciences' management team and ensure that shareholders' interests are well served. Caladrius Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Caladrius Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Mazzo, CEO, Director | ||
Catherine Vaczy, Vice President | ||
Robert Preti, CTO, Sr. VP of Manufacturing and Technical Operations and Director | ||
Eric Wei, Director | ||
Richard Berman, Independent Director | ||
Steven Myers, Independent Director | ||
Cynthia Schwalm, Director | ||
Todd Girolamo, General Counsel | ||
Gregory Brown, Director | ||
Steven Klosk, Independent Director | ||
Douglas Losordo, Chief Medical Officer | ||
Martyn Greenacre, Independent Director | ||
Joseph Talamo, CFO and Sr. VP | ||
Andrew Pecora, Chief Visionary Officer, Director | ||
Peter Traber, Independent Director | ||
Drew Bernstein, Independent Director |
Caladrius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Caladrius Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -23.84 | |||
Return On Asset | -16.73 | |||
Current Valuation | (57.88 M) | |||
Shares Outstanding | 59.78 M | |||
Shares Owned By Insiders | 2.74 % | |||
Shares Owned By Institutions | 18.51 % | |||
Number Of Shares Shorted | 543.94 K | |||
Price To Earning | (0.28) X | |||
Price To Book | 0.25 X | |||
Price To Sales | 1.00 X |
Pair Trading with Caladrius Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Caladrius Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Caladrius Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving against Caladrius Stock
0.56 | MRNA | Moderna Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Caladrius Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Caladrius Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Caladrius Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Caladrius Biosciences to buy it.
The correlation of Caladrius Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Caladrius Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Caladrius Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Caladrius Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Caladrius Biosciences information on this page should be used as a complementary analysis to other Caladrius Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Caladrius Stock
If you are still planning to invest in Caladrius Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Caladrius Biosciences' history and understand the potential risks before investing.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
CEOs Directory Screen CEOs from public companies around the world |